A Study of an Optimized Predictive and Screening System for Individualized Neoantigen Peptides Vaccine to Treat Advanced Esophageal Cancer.

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000036246

Enrollment

Unknown

Registered

2020-08-22

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced esophageal cancer

Interventions

experimental group:Personalized neoantigen peptides and Immune adjuvant

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.The patients volunteer to join in the trial and sign the informed consents; 2.Aged >= 20 years, = 3,000/µL, platelet count >= 100,000/µL, neutrophil >= 1,500/µL, hemoglobin >= 9 g/dl, total bilirubin <= 1.5 x the institutional normal upper limits, ALP, AST, ALT <= 3 x the institutional normal upper limits, creatinine <= 1.5x the institutional normal upper limits, PT <= 1.5x the institutional normal upper limits.

Exclusion criteria

Exclusion criteria: 1.Pregnant and lactating women; 2.Patients with uncontrolled active infection; 3.Patients with other malignant tumors; 4.With severe primary diseases of the heart, liver, kidney or blood system; 5.Having definite neurological/psychiatric disorder; 6.Patients who have participated in other clinical trials within 3 month; 7.Other circumstances that the investigator considered not suitable for enrollment.

Design outcomes

Primary

Measure	Time frame
Safety;	—

Secondary

Measure	Time frame
Progress free survival;Immunological index;Overall survival;	—

Countries

China

Contacts

Public ContactJie Liu

Huashan Hospital of Fudan University, Shanghai, China

jieliu@fudan.edu.cn+86 18616281372

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026